StreetInsider.com News Articles

Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026

Wed, 10 Jun 2026 05:00:00 -0400

Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy

Key Points

Superior PK: Subcutaneous administration of ADCs combined with ALT-B4 demonstrated rapid absorption, enhanced systemic exposure, and improved bioavailability compared to SC administration without ALT-B4
Reduced local toxicity: The ALT-B4 combination SC group showed a notable, dose-dependent reduction in local dermal toxicity at the injection site
Improved hematologic safety: Compared to IV infusion, the ALT-B4 combination SC group exhibited lower reductions in absolute neutrophil count (ANC) and mitigated elevations in triglycerides and AST, indicating a favorable safety profile

DAEJEON, South

Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026

Wed, 10 Jun 2026 05:00:00 -0400

Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy

Key Points

Superior PK: Subcutaneous administration of ADCs combined with ALT-B4 demonstrated rapid absorption, enhanced systemic exposure, and improved bioavailability compared to SC administration without ALT-B4
Reduced local toxicity: The ALT-B4 combination SC group showed a notable, dose-dependent reduction in local dermal toxicity at the injection site
Improved hematologic safety: Compared to IV infusion, the ALT-B4 combination SC group exhibited lower reductions in absolute neutrophil count (ANC) and mitigated elevations in triglycerides and AST, indicating a favorable safety profile

DAEJEON, South

Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026

Wed, 10 Jun 2026 05:00:00 -0400

Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy

Key Points

Superior PK: Subcutaneous administration of ADCs combined with ALT-B4 demonstrated rapid absorption, enhanced systemic exposure, and improved bioavailability compared to SC administration without ALT-B4
Reduced local toxicity: The ALT-B4 combination SC group showed a notable, dose-dependent reduction in local dermal toxicity at the injection site
Improved hematologic safety: Compared to IV infusion, the ALT-B4 combination SC group exhibited lower reductions in absolute neutrophil count (ANC) and mitigated elevations in triglycerides and AST, indicating a favorable safety profile

DAEJEON, South

Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026

Wed, 10 Jun 2026 05:00:00 -0400

Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy

Key Points

Superior PK: Subcutaneous administration of ADCs combined with ALT-B4 demonstrated rapid absorption, enhanced systemic exposure, and improved bioavailability compared to SC administration without ALT-B4
Reduced local toxicity: The ALT-B4 combination SC group showed a notable, dose-dependent reduction in local dermal toxicity at the injection site
Improved hematologic safety: Compared to IV infusion, the ALT-B4 combination SC group exhibited lower reductions in absolute neutrophil count (ANC) and mitigated elevations in triglycerides and AST, indicating a favorable safety profile

DAEJEON, South

Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026

Wed, 10 Jun 2026 05:00:00 -0400

Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy

Key Points

Superior PK: Subcutaneous administration of ADCs combined with ALT-B4 demonstrated rapid absorption, enhanced systemic exposure, and improved bioavailability compared to SC administration without ALT-B4
Reduced local toxicity: The ALT-B4 combination SC group showed a notable, dose-dependent reduction in local dermal toxicity at the injection site
Improved hematologic safety: Compared to IV infusion, the ALT-B4 combination SC group exhibited lower reductions in absolute neutrophil count (ANC) and mitigated elevations in triglycerides and AST, indicating a favorable safety profile

DAEJEON, South

Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026

Wed, 10 Jun 2026 05:00:00 -0400

Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy

Key Points

Superior PK: Subcutaneous administration of ADCs combined with ALT-B4 demonstrated rapid absorption, enhanced systemic exposure, and improved bioavailability compared to SC administration without ALT-B4
Reduced local toxicity: The ALT-B4 combination SC group showed a notable, dose-dependent reduction in local dermal toxicity at the injection site
Improved hematologic safety: Compared to IV infusion, the ALT-B4 combination SC group exhibited lower reductions in absolute neutrophil count (ANC) and mitigated elevations in triglycerides and AST, indicating a favorable safety profile

DAEJEON, South

Alteogen signs $579 million biologic licensing deal with Biogen

Wed, 25 Mar 2026 08:00:33 -0400

Alteogen Inc. (KOSDAQ: 196170) announced it has entered into an exclusive license agreement with Biogen Inc. for the development and commercialization of subcutaneous formulations of biologics using Alteogen's ALT-B4 technology.

Under the agreement, Biogen will obtain exclusive rights to develop and commercialize subcutaneous formulations for two biologic products using Alteogen's ALT-B4, which is powered by the company's Hybrozyme technology platform.

The financial terms include an upfront payment of $20 million to Alteogen, with an additional $10 million due upon initiation of development of the second product. Alteogen is eligible to receive up to $549 million in development, regulatory, and sales milestone payments

Alteogen signs $579 million biologic licensing deal with Biogen

Wed, 25 Mar 2026 08:00:33 -0400

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Wed, 25 Mar 2026 08:00:00 -0400

- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4

DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the development and commercialization of subcutaneous (SC) formulations of biologics utilizing ALT-B4 powered by Alteogen's Hybrozyme™ technology.

Under the terms of the agreement, Biogen will obtain exclusive rights to develop and commercialize SC formulations for two biologic products using Alteogen's ALT-B4 (berahyaluronidase alfa).

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Wed, 25 Mar 2026 08:00:00 -0400

- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4

Under the terms of the agreement, Biogen will obtain exclusive rights to develop and commercialize SC formulations for two biologic products using Alteogen's ALT-B4 (berahyaluronidase alfa).

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Wed, 25 Mar 2026 08:00:00 -0400

- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4

Under the terms of the agreement, Biogen will obtain exclusive rights to develop and commercialize SC formulations for two biologic products using Alteogen's ALT-B4 (berahyaluronidase alfa).

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Wed, 25 Mar 2026 08:00:00 -0400

- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4

Under the terms of the agreement, Biogen will obtain exclusive rights to develop and commercialize SC formulations for two biologic products using Alteogen's ALT-B4 (berahyaluronidase alfa).

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Wed, 25 Mar 2026 08:00:00 -0400

- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4

Under the terms of the agreement, Biogen will obtain exclusive rights to develop and commercialize SC formulations for two biologic products using Alteogen's ALT-B4 (berahyaluronidase alfa).

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Wed, 25 Mar 2026 08:00:00 -0400

- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4

Under the terms of the agreement, Biogen will obtain exclusive rights to develop and commercialize SC formulations for two biologic products using Alteogen's ALT-B4 (berahyaluronidase alfa).

Alteogen licenses hyaluronidase technology to GSK unit for $285 million

Tue, 20 Jan 2026 02:55:54 -0400

Alteogen Inc. (KOSDAQ: 196170) entered into an exclusive license agreement with Tesaro Inc., a subsidiary of GSK, for the development of a subcutaneous formulation of dostarlimab using Alteogen's ALT-B4 hyaluronidase technology.

Under the agreement, Tesaro acquired worldwide rights to use ALT-B4, which utilizes Alteogen's Hybrozyme technology, for developing and commercializing a subcutaneous version of dostarlimab, a PD-1 blocking antibody used in cancer treatment.

Alteogen will receive an upfront payment of $20 million and is eligible for milestone payments up to $265 million based on development, regulatory and sales achievements. The company will also receive royalties on sales of the commercialized product and

Alteogen licenses hyaluronidase technology to GSK unit for $285 million

Tue, 20 Jan 2026 02:55:54 -0400

Alteogen licenses hyaluronidase technology to GSK unit for $285 million

Tue, 20 Jan 2026 02:55:54 -0400

Alteogen licenses hyaluronidase technology to GSK unit for $285 million

Tue, 20 Jan 2026 02:55:54 -0400

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology